<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598959</url>
  </required_header>
  <id_info>
    <org_study_id>HXNKT 2.0</org_study_id>
    <nct_id>NCT03598959</nct_id>
  </id_info>
  <brief_title>Tofacitinib Combined With Chidamide in R/R ENKTCL</brief_title>
  <official_title>Phase I/II Study of Safety and Efficacy of Tofacitinib Combined With Chidamide in Patients With Relapsed and Refractory Extranodal Natural Killer/T Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to explore the efficacy and safety of tofacitinib combined with chidamide in
      patients with relapsed and refractory extranodal NK/T cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year progression free survival</measure>
    <time_frame>2 years after recruitment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete remission</measure>
    <time_frame>4 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events (AEs)</measure>
    <time_frame>2 years after recruitment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year overall survival</measure>
    <time_frame>2 years after recruitment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Extranodal NK/T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated with tofacitinib and chidamide for 4 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tofacitinib</intervention_name>
    <description>orally 10 mg daily</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chidamide</intervention_name>
    <description>orally 20 mg twice weekly</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Patients with primary refractory or recurrent extranodal NK/T cell lymphoma that do
             not qualify for treatment protocols of higher priority.

             2. Adequate renal function, as defined by estimated serum creatinine clearance &gt;/=50
             ml/min and/or serum creatinine &lt;/= 1.8 mg/dL.

             3. Adequate hepatic function, as defined by serum glutamate oxaloacetate transaminase
             (SGOT) and/or serum glutamate pyruvate transaminase (SGPT) &lt;/= 3 x upper limit of
             normal; serum bilirubin and alkaline phosphatase &lt;/= 2 x upper limit of normal.

             4.. Adequate cardiac function with left ventricular ejection fraction &gt;/= 50%. No
             uncontrolled arrhythmias or symptomatic cardiac disease.

             5. Performance status 0-1. 6. Negative Beta diffusing capacity of lung for carbon
             monoxide (HCG) text in a woman with child-bearing potential, defined as not
             post-menopausal for 12 months or no previous surgical sterilization

        Exclusion Criteria:

        -1. Patients relapsed after allogeneic stem cell transplant 2. Patients with active
        hepatitis B or C(HBV DNA &gt;/=10,000 copies/mL). 3. Active infection requiring parenteral
        antibiotics 4. HIV infection, unless the patient is receiving effective antiretroviral
        therapy with undetectable viral load and normal cluster of differentiation 4 (CD4) counts
        5. Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic
        hepatitis C or positive hepatitis C serology.

        6. Patients with a cQT longer than 500 ms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jie Ji, MD</last_name>
    <phone>86-28-85422373</phone>
    <email>jieji@scu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ting Niu, MD</last_name>
    <phone>86-28-85422373</phone>
    <email>tingniu@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Lee S, Park HY, Kang SY, Kim SJ, Hwang J, Lee S, Kwak SH, Park KS, Yoo HY, Kim WS, Kim JI, Ko YH. Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. Oncotarget. 2015 Jul 10;6(19):17764-76.</citation>
    <PMID>25980440</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 24, 2018</last_update_submitted>
  <last_update_submitted_qc>July 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan University</investigator_affiliation>
    <investigator_full_name>Jie Ji</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

